These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 38181791)

  • 1. Olgotrelvir, a dual inhibitor of SARS-CoV-2 M
    Mao L; Shaabani N; Zhang X; Jin C; Xu W; Argent C; Kushnareva Y; Powers C; Stegman K; Liu J; Xie H; Xu C; Bao Y; Xu L; Zhang Y; Yang H; Qian S; Hu Y; Shao J; Zhang C; Li T; Li Y; Liu N; Lin Z; Wang S; Wang C; Shen W; Lin Y; Shu D; Zhu Z; Kotoi O; Kerwin L; Han Q; Chumakova L; Teijaro J; Royal M; Brunswick M; Allen R; Ji H; Lu H; Xu X
    Med; 2024 Jan; 5(1):42-61.e23. PubMed ID: 38181791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19.
    Jiang R; Han B; Xu W; Zhang X; Peng C; Dang Q; Sun W; Lin L; Lin Y; Fan L; Lv D; Shao L; Chen Y; Qiu Y; Han L; Kong W; Li G; Wang K; Peng J; Lin B; Tong Z; Lu X; Wang L; Gao F; Feng J; Li Y; Ma X; Wang J; Wang S; Shen W; Wang C; Yan K; Lin Z; Jin C; Mao L; Liu J; Kushnareva Y; Kotoi O; Zhu Z; Royal M; Brunswick M; Ji H; Xu X; Lu H
    NEJM Evid; 2024 Jun; 3(6):EVIDoa2400026. PubMed ID: 38804790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L.
    Ma XR; Alugubelli YR; Ma Y; Vatansever EC; Scott DA; Qiao Y; Yu G; Xu S; Liu WR
    ChemMedChem; 2022 Jan; 17(1):e202100456. PubMed ID: 34242492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new generation M
    Huang C; Shuai H; Qiao J; Hou Y; Zeng R; Xia A; Xie L; Fang Z; Li Y; Yoon C; Huang Q; Hu B; You J; Quan B; Zhao X; Guo N; Zhang S; Ma R; Zhang J; Wang Y; Yang R; Zhang S; Nan J; Xu H; Wang F; Lei J; Chu H; Yang S
    Signal Transduct Target Ther; 2023 Mar; 8(1):128. PubMed ID: 36928316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Inhibitors of Main Protease (M
    Mondal S; Chen Y; Lockbaum GJ; Sen S; Chaudhuri S; Reyes AC; Lee JM; Kaur AN; Sultana N; Cameron MD; Shaffer SA; Schiffer CA; Fitzgerald KA; Thompson PR
    J Am Chem Soc; 2022 Nov; 144(46):21035-21045. PubMed ID: 36356199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
    Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
    ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.
    Dampalla CS; Zheng J; Perera KD; Wong LR; Meyerholz DK; Nguyen HN; Kashipathy MM; Battaile KP; Lovell S; Kim Y; Perlman S; Groutas WC; Chang KO
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34210738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1.
    Xie X; Lan Q; Zhao J; Zhang S; Liu L; Zhang Y; Xu W; Shao M; Peng J; Xia S; Zhu Y; Zhang K; Zhang X; Zhang R; Li J; Dai W; Ge Z; Hu S; Yu C; Wang J; Ma D; Zheng M; Yang H; Xiao G; Rao Z; Lu L; Zhang L; Bai F; Zhao Y; Jiang S; Liu H
    Signal Transduct Target Ther; 2024 Mar; 9(1):54. PubMed ID: 38443334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies.
    Tan B; Joyce R; Tan H; Hu Y; Wang J
    Acc Chem Res; 2023 Jan; 56(2):157-168. PubMed ID: 36580641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development.
    Zhao MM; Yang WL; Yang FY; Zhang L; Huang WJ; Hou W; Fan CF; Jin RH; Feng YM; Wang YC; Yang JK
    Signal Transduct Target Ther; 2021 Mar; 6(1):134. PubMed ID: 33774649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blue Biotechnology: Computational Screening of
    Ibrahim MAA; Abdelrahman AHM; Atia MAM; Mohamed TA; Moustafa MF; Hakami AR; Khalifa SAM; Alhumaydhi FA; Alrumaihi F; Abidi SH; Allemailem KS; Efferth T; Soliman ME; Paré PW; El-Seedi HR; Hegazy MF
    Mar Drugs; 2021 Jul; 19(7):. PubMed ID: 34356816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 M
    Qiao J; Li YS; Zeng R; Liu FL; Luo RH; Huang C; Wang YF; Zhang J; Quan B; Shen C; Mao X; Liu X; Sun W; Yang W; Ni X; Wang K; Xu L; Duan ZL; Zou QC; Zhang HL; Qu W; Long YH; Li MH; Yang RC; Liu X; You J; Zhou Y; Yao R; Li WP; Liu JM; Chen P; Liu Y; Lin GF; Yang X; Zou J; Li L; Hu Y; Lu GW; Li WM; Wei YQ; Zheng YT; Lei J; Yang S
    Science; 2021 Mar; 371(6536):1374-1378. PubMed ID: 33602867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses.
    Jeong JH; Choi JH; Kim BK; Min SC; Chokkakula S; Oh S; Park JH; Shim SM; Kim EG; Choi YK; Lee JY; Baek YH; Song MS
    Antiviral Res; 2023 Aug; 216():105669. PubMed ID: 37437781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olgotrelvir, a dual inhibitor of SARS-CoV-2 M
    Mao L; Shaabani N; Zhang X; Jin C; Xu W; Argent C; Kushnareva Y; Powers C; Stegman K; Liu J; Xie H; Xu C; Bao Y; Xu L; Zhang Y; Yang H; Qian S; Hu Y; Shao J; Zhang C; Li T; Li Y; Liu N; Lin Z; Wang S; Wang C; Shen W; Lin Y; Shu D; Zhu Z; Kotoi O; Kerwin L; Han Q; Chumakova L; Teijaro J; Royal M; Brunswick M; Allen R; Ji H; Lu H; Xu X
    Med; 2024 Feb; 5(2):169-171. PubMed ID: 38340710
    [No Abstract]   [Full Text] [Related]  

  • 17. Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model.
    Tan B; Zhang X; Ansari A; Jadhav P; Tan H; Li K; Chopra A; Ford A; Chi X; Ruiz FX; Arnold E; Deng X; Wang J
    Science; 2024 Mar; 383(6690):1434-1440. PubMed ID: 38547259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2.
    Li Y; Wang K; Sun H; Wu S; Wang H; Shi Y; Li X; Yan H; Yang G; Wu M; Li Y; Ding X; Si S; Jiang J; Du Y; Li Y; Hong B
    Antiviral Res; 2023 Jun; 214():105606. PubMed ID: 37076089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity.
    Hamdy R; Fayed B; Mostafa A; Shama NMA; Mahmoud SH; Mehta CH; Nayak Y; M Soliman SS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19.
    Allerton CMN; Arcari JT; Aschenbrenner LM; Avery M; Bechle BM; Behzadi MA; Boras B; Buzon LM; Cardin RD; Catlin NR; Carlo AA; Coffman KJ; Dantonio A; Di L; Eng H; Farley KA; Ferre RA; Gernhardt SS; Gibson SA; Greasley SE; Greenfield SR; Hurst BL; Kalgutkar AS; Kimoto E; Lanyon LF; Lovett GH; Lian Y; Liu W; Martínez Alsina LA; Noell S; Obach RS; Owen DR; Patel NC; Rai DK; Reese MR; Rothan HA; Sakata S; Sammons MF; Sathish JG; Sharma R; Steppan CM; Tuttle JB; Verhoest PR; Wei L; Yang Q; Yurgelonis I; Zhu Y
    J Med Chem; 2024 Aug; 67(16):13550-13571. PubMed ID: 38687966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.